Business - Monitor   

Novo Nordisk cuts prices of insulin

CHENNAI: Novo Nordisk India, world leader in diabetes care, announced that it was reducing the prices of its locally filled human insulin vials (40 iu) by about Rs. 50 to Rs. 145 in India. This had been done keeping in mind the abiding philosophy of the company that access to diabetes therapy must improve, especially in the developing world, according to its managing director Anil Kapur. Since 1998 the company had not increased the prices of its insulin despite competitors constantly doing so, Dr. Kapur has stated in a release.

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• Panel to look into timely credit to handloom sector
• Pepsi given go ahead to acquire a franchisee
• Jagson Airlines becomes scheduled airline
• RBI sets terms to clear TMB cobweb
• Reliance Infocomm to appoint agents
• T+2 rolling settlement from April 1
• Late selling pulls Sensex down
• GTSL allots shares against warrants
• Whirlpool to expand distribution network in South
• Two JPCs — Identical reference but contrasting approach
• Stock Market Index
• Exchange rates
• Bullion rates
• Dr. Reddy's starts shipment of Ibuprofen
• Novo Nordisk cuts prices of insulin
• Malladi places equity with IL&FS group
• Sun Pharma to buyback shares
• CPCL technical director

Copyright © 2003, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu